Amgen reports Imdelltra combination cut death risk 58% in lung cancer trial

The short version

• Amgen says adding Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in extensive-stage small cell lung cancer.[CNBC]
• Median overall survival reached 21.1 months with the combination versus 12.7 months with Imfinzi alone, and Amgen reported nearly 80% of patients were alive at one year versus 53%.[CNBC]
• The full results were presented at the European Society for Medical Oncology Congress, and the study did not test the combination against other first-line approaches.[CNBC]

Key facts

• Amgen stated that adding Imdelltra to Imfinzi reduced the risk of death by 58% in extensive-stage small cell lung cancer patients.[CNBC]
• The trial found median overall survival of 21.1 months with the combination compared with 12.7 months with Imfinzi alone.[CNBC]
• Amgen reported that nearly 80% of patients taking both drugs were alive at one year, compared with 53% receiving Imfinzi alone.[CNBC]
• The study was presented at the European Society for Medical Oncology Congress and did not test whether the combination was better than other first-line treatment approaches.[CNBC]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancerCNBC